Methods and compositions for treating amyloid-related diseases
View Patent ↗Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.
1. A compound of Formula I:
wherein:
R 1 is a substituted or unsubstituted bicyclo [2.1.2] heptyl or substituted or unsubstituted adamantyl, wherein said substituted adamantyl is substituted with alkenyl, alkynyl, halogeno, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, imino, sulfnydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, alkylaryl, or aryl;
R 2 is hydrogen or alkyl;
Y is SO 3 − X + ;
X + is hydrogen or a cationic group; and
each of L 1 and L 1 is independently a substituted or unsubstituted C 1 -C 5 alkyl group or absent; or a pharmaceutically acceptable salt, ester or prodrug thereof.
2. A compound of Formula II:
wherein:
R 1 is a substituted or unsubstituted bicyclo [2.1.2] heptyl or substituted or unsubstituted adamantyl, wherein said substituted adamantyl is substituted with alkenyl, alkynyl, halogeno, hydroxyl, alkylcarbonyloxy arylcarbonyloxy, alkoxycarbonyloxy, aryloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, alkylaryl, or aryl,
R 2 is hydrogen, alkyl, mercaptoalkyl, alkenyl, alkynyl, cycloalkyl, aryl, or arylalkyl;
Y is SO 3 − X + ;
X + is hydrogen, a cationic group, or an ester forming moiety;
m is 0;
n is 1, 2, 3, or 4;
L is substituted or unsubstituted C 1 -C 3 alkyl group or absent; or a pharmaceutically acceptable salt, ester or prodrug thereof.
3. The compound of claim 1 or 2 , wherein R 2 is hydrogen.
4. The compound of claim 1 or 2 , wherein R 1 is adamantyl.
5. The compound of claim 1 or 2 , wherein R 1 is bicyclo[2.1.2]heptyl.
6. The compound of claim 1 , wherein L 1 is CH 2 CH 2 .
7. The compound of claim 1 or 2 , wherein L 1 is absent.
8. The compound of claim 1 or 2 , wherein said compound is:
or a pharmaceutically acceptable salt, ester, or prodrug thereof.
9. A method of treating Alzheimer's disease in a subject comprising administering to a subject in need thereof a compound of claim 1 in an amount effective to treat Alzheimer's disease.
10. The method of claim 9 , wherein the therapeutic compound is administered orally.
11. The method of claim 9 , wherein said therapeutic compound is administered in a pharmaceutically acceptable vehicle.
12. A pharmaceutical composition comprising a compound according to claim 1 .
13. The method of claim 9 , wherein said subject is a human.
14. The pharmaceutical composition of claim 12 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable acid, base, buffering agent, inorganic salt, solvent, or preservative.
15. The pharmaceutical composition of claim 12 , wherein said compound is dissolved in a liquid pharmaceutically acceptable vehicle.
16. The pharmaceutical composition of claim 12 , wherein said compound is present as a homogenous mixture in a capsule or pill.
17. A compound according to claim 1 , wherein said compound is 3-(1-adamantyl)amino-1-propanesulfonic acid.
18. A compound of Formula II:
wherein:
R 1 is a substituted or unsubstituted adamantyl group,
R 2 is alkyl, mercaptoalkyl, alkenyl, alkynyl, cycloalkyl, aryl, or arylalkyl;
Y is OSO 3 − X + or SSO 3 − X + ;
X + is hydrogen, a cationic group, or an ester forming moiety;
m is 0;
n is 1, 2, 3, or 4;
L is substituted or unsubstituted C 1 -C 3 alkyl group or absent; or a pharmaceutically acceptable salt, aster or prodrug thereof.
19. A compound of Formula II:
wherein:
R 1 is a substituted or unsubstituted bicyclo[2.1.2] heptyl or substituted or unsubstituted adamantyl group,
R 2 is alkyl, mercaptoalkyl, alkenyl, alkynyl, cycloalkyl, aryl, or arylalkyl;
Y is SO 3 − X + ;
X + is hydrogen, a cationic group, or an ester forming moiety;
m is 0;
n is 1, 2, or 4;
L is substituted or unsubstituted C 1 -C 3 alkyl group or absent; or a pharmaceutically acceptable salt, ester or prodrug thereof.
20. The compound of claim 19 , wherein n is 4.
21. The compound of claim 19 , wherein L is absent.
22. The compound of claim 1 , wherein L 1 is CH 2 CH 2 CH 2 .
23. A pharmaceutical composition comprising a compound according to any one of claims 2 , 8 , 17 , 18 , or 19 .
24. The pharmaceutical composition of claim 12 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable vehicle.
25. The pharmaceutical composition of claim 23 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable acid, base, buffering agent, inorganic salt, solvent, or preservative.
26. The pharmaceutical composition of claim 23 , wherein said compound is dissolved in a liquid pharmaceutically acceptable vehicle.
27. The pharmaceutical composition of claim 23 , wherein said compound is present as a homogenous mixture in a capsule or pill.
28. The pharmaceutical composition of claim 23 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable vehicle.
29. A method of treating Alzheimer's disease in a subject comprising administering to a subject in need thereof a compound of any one of claims 2 , 8 , 17 , 18 , or 19 in an amount effective to treat Alzheimer's disease.
30. The method of claim 29 , wherein the therapeutic compound is administered orally.
31. The method of claim 29 , wherein said therapeutic compound is administered in a pharmaceutically acceptable vehicle.
32. The method of claim 29 , wherein said subject is a human.